Keep pulling the thread on Mike Stadnisky.
Mike Stadnisky observes that many publicly traded life science tools companies are trading under a $100 million market cap, which he attributes to a 'disease' of overfunding and the removal of founder control during their private stages.
Mike Stadnisky of Tielson Capital states that the traditional venture capital model, where only 1 in 10 companies are expected to succeed, is an unacceptable model for the life sciences industry.
Tielson Capital's investment strategy focuses on life science tools companies that can generate revenue early by commercializing products for 'research use only' (RUO) markets.
Mike Stadnisky believes that many life science startups are currently in distress because over-capitalization in previous years has become 'the noose that they're hanging themselves by'.
Mike Stadnisky advises startups to use major industry conferences, such as the JP Morgan Healthcare Conference, as deadlines to accelerate and finalize partnership announcements with larger companies.
Mike Stadnisky cites Elizabeth Holmes as a notable example of the 'fake it till you make it' approach failing catastrophically in the biotech industry.
Mike Stadnisky asserts that successful business development partnerships, driven by shared customers, often serve as the initial foundation for future M&A discussions.
The company Flojo, previously led by Mike Stadnisky, was acquired by Becton, Dickinson (BD).
A potential partner of Flojo inserted a right of first refusal (ROFR) clause into a partnership contract, signaling a long-term strategic interest in acquiring the company.
Mike Stadnisky believes that cap table management platforms like Carta do not replace the need for a corporate attorney to review legal documents.
Mike Stadnisky states that when a large company acquires a startup, the startup's indirect cost rate can increase from approximately 30% to as high as 45-55% overnight.
Mike Stadnisky strongly advises against using top-down financial modeling, which is based on capturing a percentage of a total addressable market (TAM), calling the approach 'stupid' and not a real strategy.